| Structural highlights
6u18 is a 2 chain structure with sequence from "bacillus_coli"_migula_1895 "bacillus coli" migula 1895. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
| | Ligands: | , |
| Gene: | mphR(A), mphR, A9R57_28010, ACN77_02555, ACN77_03810, ACN77_19745, AKG29_00740, AM465_27045, APT94_14580, B1K96_22845, B9M99_28120, B9N33_26285, B9T59_28650, BANRA_01808, BANRA_05330, BANRA_05395, BE963_00530, BEN53_26070, BET08_23460, BFD68_26430, BJJ90_27670, BK248_28255, BK292_28800, BK334_26705, BK373_25645, BK375_28450, BK383_16415, BK400_25090, BVL39_07785, BVL39_26565, C5N07_27930, C5P01_27745, C5P43_14800, C5P44_28315, C6669_28285, C6986_31345, C7235_25300, C7235_26770, CQP61_00550, CR538_26710, CRT43_27530, CRT46_27035, CWS33_26295, D0X26_00055, D0X26_28400, D3O91_28140, D9N32_01235, DB359_27590, DBY14_07355, DBY14_07475, DBY14_07595, DBY14_07715, DBY14_07835, DBY14_07955, DBY14_08075, DBY14_08195, DBY14_08400, DBY14_09000, DBY14_09120, DBY14_09240, DBY14_09360, DBY14_09480, DBY14_09600, DBY14_09720, DBY14_09840, DBY14_09960, DBY14_10080, DBY14_10200, DBY14_10320, DBY14_10440, DBY14_10560, DBY14_10680, DBY14_10800, DBY14_10920, DBY14_11040, DBY14_11160, DBY14_11280, DL545_01125, DL545_26270, DM102_26995, DM129_26600, DM129_28140, DNQ41_27340, DS732_30515, E4Z89_24290, Eco118UI_26585, ECONIH1_26780, ECTO124_05297, EGT48_01470, EIA21_26670, EJC48_00900, EJC75_00560, EJH97_25820, EPS71_24560, EQ823_24865, EQ830_27025, ERS085366_04056, ERS085404_05054, ERS150873_04751, ETN48_p0081, EVY21_24885, ExPECSC022_02556, ExPECSC036_03428, ExPECSC065_05093, EXX13_27025, EYD11_23970, FORC82_p029, HmCmsJML146_04799, HMPREF3040_01640, MS6198_B124, MS8345_A00020, NCTC13846_04922, U12A_A00163, U14A_A00115, UN86_19865, YDC107_4984 ("Bacillus coli" Migula 1895) |
| Resources: | FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT |
Publication Abstract from PubMed
Clarithromycin is an improved semisynthetic analogue of the naturally occurring macrolide, erythromycin. The subtle modification of a methyl group on the C-6 hydroxyl group endows the molecule with improved acid stability and results in a clinically useful antibiotic. Here, we show that the effector specificity of the biosensor protein, MphR, can be evolved to selectively recognize clarithromycin and therefore report on the production of this molecule in vivo. In addition, a crystal structure of the evolved variant reveals the molecular basis for selectivity and provides a guide for the evolution of a new metabolic function using this biosensor.
Development of Genetically Encoded Biosensors for Reporting the Methyltransferase-Dependent Biosynthesis of Semisynthetic Macrolide Antibiotics.,Li Y, Reed M, Wright HT, Cropp TA, Williams GJ ACS Synth Biol. 2021 Sep 21. doi: 10.1021/acssynbio.1c00151. PMID:34546703[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Li Y, Reed M, Wright HT, Cropp TA, Williams GJ. Development of Genetically Encoded Biosensors for Reporting the Methyltransferase-Dependent Biosynthesis of Semisynthetic Macrolide Antibiotics. ACS Synth Biol. 2021 Sep 21. doi: 10.1021/acssynbio.1c00151. PMID:34546703 doi:http://dx.doi.org/10.1021/acssynbio.1c00151
|
